HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dumas, J.-L. Articles by Goldlust, D. Search for Related Content PubMed PubMed Citation Articles by Dumas, J.-L. Articles by Goldlust, D.

Central Nervous System Sarcoidosis: Follow-up at MR Imaging during Steroid Therapy¹

¹ From the Departments of Radiology (J.L.D., M.B., D.G.), Pneumology (D.V., H.T.L.), and Neurology (C.B.), Hôpital Avicenne, 125 route de Stalingrad, 93009 Bobigny, France; and the Department of Internal Medicine, Groupe Hospitalier Pitié-Salpêtrière, Paris, France (C.C.A., J.C.P.). Received July 31, 1998; revision requested September 1; revision received May 5, 1999; accepted July 14. Address reprint requests to J.L.D.

PURPOSE: To document the changes observed at sequential magnetic resonance (MR) imaging of sarcoidosis lesions of the central nervous system (CNS) during treatment with corticosteroids.

MATERIALS AND METHODS: The abnormalities detected in 24 patients (mean follow-up, 36 months) were compared before and after therapeutic periods (n = 75) that were divided into attack (high-dose), upkeep (decreased-dose), and minimal (low-dose) periods. Parenchymal lesions were classified as type 1 (enhanced with gadolinium), type 2 (demyelinating), or type 3 (lacunar) and were assessed as regressing, stable, or progressing.

RESULTS: Seven of the 24 patients had several types of lesions. Isolated type 3 lesions (six patients) were the only lesions not associated with neurologic deficit. Type 1 lesions (13 patients) regressed in 22 of 22 attack periods and progressed in nine of 27 upkeep and minimal periods. MR imaging depicted relapses in patients with multifocal CNS involvement or long-standing CNS impairment or in those who had previously received steroid therapy. Type 2 (seven patients) and type 3 (13 patients) lesions remained stable in 68 of 68 therapeutic periods. Type 1 lesions appeared in three patients with type 2 and type 3 lesions during two upkeep and three minimal periods. Findings at follow-up MR imaging contributed to the reintroduction of high-dose corticosteroid therapy in eight patients.

CONCLUSION: MR imaging can be used to differentiate between reversible and irreversible lesions in CNS sarcoidosis. MR imaging can be a useful tool for adjusting treatment to prevent irreversible CNS damage.

Index terms: Brain, MR, 10.121411, 10.121412, 10.12143 • Sarcoidosis, 10.22, 30.22 • Skull, MR, 122.121411, 122.121412, 122.12143 • Spine, MR, 30.121411, 30.121412, 30.12143 • Steroids • Vasculitis, 17.62

This article has been cited by other articles:

				M. K. Demir, F. V. Aker, O. Akinci, and A. Ozgultekin Case 134: Primary Leptomeningeal Melanomatosis Radiology, June 1, 2008; 247(3): 905 - 909. [Full Text] [PDF]

				F G Joseph and N J Scolding Sarcoidosis of the nervous system Practical Neurology, August 1, 2007; 7(4): 234 - 244. [Abstract] [Full Text] [PDF]

				J. K. Smith, M. G. Matheus, and M. Castillo Imaging Manifestations of Neurosarcoidosis Am. J. Roentgenol., February 1, 2004; 182(2): 289 - 295. [Full Text] [PDF]

				E. S. White and J. P. Lynch III Sarcoidosis Involving Multiple Systems : Diagnostic and Therapeutic Challenges Chest, May 1, 2001; 119(5): 1593 - 1597. [Full Text] [PDF]